Clinical comparison of all FDA-approved immunoglobulin products for providers. Compare concentration, IgA content, stabilizer, sugar content, osmolality, storage, FDA-approved indications, and compatibility considerations. Sources: FDA prescribing information.
Privigen
CSL Behring IV Every 3–4 weeks
Conc: 10% IgA: ≤25 mcg/mL Sugar: None
L-proline stabilized; very low IgA (≤25 mcg/mL); no sugar; FDA-approved for CIDP and PIDD
Gamunex-C
Grifols IV / SC Every 3–4 weeks (IV) or weekly (SC)
Conc: 10% IgA: 46 mcg/mL average Sugar: None
Dual IV/SC route; caprylate-stabilized; approved for CIDP, PIDD, ITP
Gammagard Liquid
Takeda IV / SC Every 3–4 weeks (IV) or weekly (SC)
Conc: 10% IgA: 37 mcg/mL average Sugar: None
Dual IV/SC route; glycine-stabilized; 10% concentration
Gammagard S/D
Takeda IV Every 3–4 weeks
Conc: 5% or 10% (reconstituted) IgA: <1 mcg/mL (5%) — lowest available Sugar: SUCROSE — renal risk
Lyophilized; lowest IgA option; 5% or 10%; CONTAINS SUCROSE
Octagam
Octapharma IV Every 3–4 weeks
Conc: 5% and 10% IgA: ≤200 mcg/mL (10%) Sugar: 5%: maltose; 10%: none
5% and 10%; maltose-containing (5%); caution with glucose monitoring
Gammaplex
Grifols IV Every 3–4 weeks
Conc: 5% and 10% IgA: <10 mcg/mL (5%); ≤20 mcg/mL (10%) Sugar: None
5% and 10%; sorbitol-stabilized; no sugar; approved for PIDD and ITP
Panzyga
Octapharma IV Every 3–4 weeks
Conc: 10% IgA: ≤100 mcg/mL Sugar: None
10%; glycine-stabilized; approved for PIDD and ITP
Bivigam
ADMA Biologics IV Every 3–4 weeks
Conc: 10% IgA: Not specified (traces) Sugar: None
10% liquid; glycine-stabilized; approved for PIDD
Asceniv
ADMA Biologics IV Every 3–4 weeks
Conc: 10% IgA: Not specified (traces) Sugar: None
Standardized high-titer anti-pneumococcal antibodies; for PIDD patients with recurrent infections
Flebogamma DIF
Grifols IV Every 3–4 weeks
Conc: 5% and 10% IgA: ≤50 mcg/mL Sugar: None
5% and 10%; sorbitol-free (unlike Gammaplex); D-sorbitol–free formulation
Gammaked
Grifols IV / SC Every 3–4 weeks (IV) or weekly (SC)
Conc: 10% IgA: 46 mcg/mL average Sugar: None
Dual IV/SC route; same formulation as Gamunex-C; approved for CIDP, PIDD, ITP
Hizentra
CSL Behring SC Weekly or biweekly
Conc: 20% IgA: ≤50 mcg/mL Sugar: None
20% SC; home self-infusion; L-proline stabilized; approved for PIDD and CIDP
HyQvia
Takeda SC (facilitated) Monthly
Conc: 10% IG + hyaluronidase IgA: 37 mcg/mL average Sugar: None
Monthly SC dosing via recombinant hyaluronidase; approved for PIDD
Cuvitru
Takeda SC Weekly
Conc: 20% IgA: 80 mcg/mL average Sugar: None
20% SC; room temperature storage; approved for PIDD
Cutaquig
Octapharma SC Weekly
Conc: 16.5% IgA: ≤600 mcg/mL Sugar: None
16.5% SC; maltose-free; approved for PIDD
Xembify
Grifols SC Weekly
Conc: 20% IgA: ≤10 mcg/mL — one of the lowest for SC products Sugar: None
20% SC; low IgA; approved for PIDD
Clinical data sourced from FDA-approved prescribing information. Verify current product labeling before clinical decisions.